Ceftobiprole medocaril for treating hospital-acquired pneumonia or community-acquired pneumonia requiring hospitalisation in children

Ceftobiprole medocaril is in clinical development for the treatment of paediatric community-acquired pneumonia (CAP) or hospital-acquired pneumonia (HAP) requiring hospitalisation. Pneumonia is a type of chest infection where tiny air sacs in your lungs, called alveoli, get inflamed and fill with fluid, making it harder to breathe. The most common type of pneumonia is CAP- where pneumonia affects somebody not in hospital. HAP is when pneumonia develops while you’re in hospital being treated for another condition. Many kinds of bacteria and viruses can cause pneumonia. Symptoms of pneumonia include coughing, feeling unwell and tired, a high temperature, difficulty breathing, chest pain or discomfort and loss of appetite. In adult patients, morbidity and mortality has been reduced. However, paediatric mortality and hospital admissions remain high, with the disease claiming the lives of around 40 children in England and Wales each year.